ArticleFrontiers in oncology2023

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial.

Jinglei Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.